CIK 0000943819 · Large accelerated filer
RESMED INC
Sign in to watch- Tickers
- RMD RSMDF
- Exchange
- NYSE, OTC
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 980152841
- Phone
- 8587462400
- Business address
- 9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA, 92123
Securities
- RMD ResMed Inc. Common Stock NYSE
- RSMDF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $3,744,605
- in 5 filings, $3.7M under 10b5-1 plans
Net −$3,744,605. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-09 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +683 | $146.34 | $100K | 480,486 |
| 2026-11-09 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,310 | $146.34 | $631K | 484,796 |
| 2026-11-09 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,993 | $235.35 | $1.2M | 479,803 |
| 2026-11-09 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −683 | 4,310 | ||
| 2026-11-09 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,310 | 0 | ||
| 2026-10-23 | Rider Michael J Global General Counsel | Sale 10b5-1 | −400 | $255.00 | $102K | 12,318 |
| 2026-10-07 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 484,794 |
| 2026-10-07 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $226.33 | $1.1M | 479,803 |
| 2026-10-07 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 4,993 | ||
| 2026-09-08 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 471,247 |
| 2026-09-08 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $222.44 | $1.1M | 466,256 |
| 2026-09-08 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 9,984 | ||
| 2026-09-02 | FARRELL PETER C Director | Sale 10b5-1 | −970 | $234.73 | $228K | 51,803 |
| 2026-08-14 | Leong Justin Chief Product Officer | Grant or award | +6,461 | 35,489 | ||
| 2026-08-14 | Rider Michael J Global General Counsel | Grant or award | +3,230 | 12,718 | ||
| 2026-08-14 | Farrell Michael J. Chairman and CEO | Grant or award | +13,547 | 479,803 | ||
| 2026-08-14 | Bloomer Aaron Chief Financial Officer | Grant or award | +9,072 | 9,072 | ||
| 2026-08-07 | Farrell Michael J. Chairman and CEO | Option exercise 10b5-1 | +4,991 | $146.34 | $730K | 471,247 |
| 2026-08-07 | Farrell Michael J. Chairman and CEO | Sale 10b5-1 | −4,991 | $205.69 | $1.0M | 466,256 |
| 2026-08-07 | Farrell Michael J. Chairman and CEO | Option exercise · ResMed Common Stock Options 10b5-1 | −4,991 | 14,975 |
Page 1 of 18 · 355 trades